American Journal of Biomedicine and Pharmacy
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

The Importance of Thromboxane in Medicine

Muhammadieva Nafisa Otabek kizi
Samarkand State Medical University student

Sovetov Korakul Tashanovich
Candidate of Medical Sciences Associate Professor

Received: 2024, 15, Feb
Accepted: 2025, 21, Mar
Published: 2025, 14, Apr

Annotation: Thromboxane A2 (TXA2), a biologically active lipid compound from the prostaglandin family, plays a critical role in hemostasis, vascular tone regulation, and inflammatory processes. Primarily produced by platelets, TXA2 promotes platelet aggregation and vasoconstriction, both of which are essential for preventing blood loss but may also contribute to pathological clot formation. Despite growing recognition of thromboxane's functions, further understanding is needed regarding its pathological overproduction and clinical control in inflammatory and cardiovascular conditions. This study aims to explore the biological and clinical significance of thromboxane A2, its mechanisms of action, and therapeutic interventions targeting it. TXA2 enhances platelet aggregation and vasoconstriction, which, while beneficial in acute bleeding, can increase the risk of thrombosis, myocardial infarction, and stroke under excessive production. Anti-thromboxane drugs such as aspirin inhibit TXA2 synthesis, thereby reducing clot formation and offering protective effects in cardiovascular diseases and inflammatory disorders such as arthritis and asthma. The article highlights TXA2's dual role in both protective hemostasis and pathological thrombosis, emphasizing the importance of monitoring and managing its levels clinically.

Keywords: thromboxane, thrombus, blood, arthritis, asthma, blood clotting.

Introduction

Thromboxane A2 stimulates the aggregation of platelets, which is important in the blood clotting process. It ensures that platelets stick together and form thrombus in blood vessels. Thromboxane A2 has the properties of constricting blood vessels, which helps to increase blood pressure. This process is especially important in cases of blood loss or shock [1].

Thromboxane A2 is also involved in inflammatory processes. It plays a role in the development of inflammation and the immune response [2]. Excessive production of thromboxane A2 can lead to increased blood coagulation and thrombus formation. Therefore, drugs used as thromboxane inhibitors, such as aspirin, are important in reducing blood clotting and preventing cardiovascular disease. High levels of thromboxane A2 may increase the risk of cardiovascular diseases such as heart attack and stroke [3]. Therefore, it is important to control the level of thromboxane and use drugs to reduce it. Because thromboxane A2 is involved in inflammatory processes, it can be used as a thromboxane inhibitor in inflammatory diseases such as arthritis and asthma.[4]

Methodology

The methodology of this article is based on a qualitative synthesis of current scientific literature, clinical studies, and pharmacological reports to examine the role and medical significance of thromboxane A2 (TXA2). A systematic review approach was applied to gather and analyze data from various peer-reviewed journals, experimental studies, and clinical trials focusing on thromboxane's physiological functions, pathological mechanisms, and pharmacological interventions. Primary sources included internationally recognized medical journals and clinical databases where studies investigating the biochemical nature of thromboxane, its production in platelets, and its involvement in coagulation and inflammation were examined. Emphasis was placed on the clinical impact of TXA2 in cardiovascular diseases such as myocardial infarction, stroke, and hypertension, as well as its role in inflammatory diseases like arthritis and asthma. The methodology also incorporated critical evaluation of therapeutic strategies, particularly the use of thromboxane inhibitors such as aspirin, assessing their mechanisms of action, efficacy, and outcomes in reducing thrombotic risk. Furthermore, recent research exploring the potential association between thromboxane levels and metabolic syndrome or cancer was included to expand the understanding of its systemic influence. Relevant studies were selected based on their scientific rigor, publication in reputable journals, and relevance to the core themes of TXA2's clinical application. The analysis aimed to provide a comprehensive understanding of TXA2 from both biological and clinical perspectives, offering insights into its dual role in health and disease, while identifying future directions for medical research and pharmaceutical development targeting thromboxane pathways.

Results and Discussion

Many clinical trials are underway to investigate the role of thromboxane A2. These studies aim to determine the role of thromboxane in various diseases, including cancer and metabolic syndrome.[6]

Thromboxane A2 (TXA2) plays an important role in cardiovascular diseases. Thromboxane A2 is produced by platelets and stimulates blood clotting. It increases platelet aggregation, which is important in cases of blood loss. However, if the level of thromboxane A2 is excessive, it can lead to increased blood clotting and thrombus formation. Thromboxane A2 narrows blood vessels, which increases blood pressure [7]. If the blood vessels become permanently narrowed, it can lead to hypertension (high blood pressure) and cardiovascular disease. Excessive production of thromboxane A2 increases the risk of cardiovascular diseases, such as heart attack and stroke. High levels of thromboxane A2 increase blood clot formation, which can block blood

flow. Thromboxane A2 is also involved in inflammatory processes. Inflammation plays an important role in the development of cardiovascular diseases. The role of thromboxane A2 in inflammatory processes may contribute to the development of atherosclerosis (fat accumulation in blood vessels). [8]

Medications used to reduce the effects of thromboxane A2, such as aspirin, are important in preventing cardiovascular disease. Aspirin inhibits the production of thromboxane A2, which reduces the formation of blood clots and reduces the risk of cardiovascular diseases [9]. Thromboxane A2 plays an important role in cardiovascular diseases, as it stimulates blood clotting, narrows blood vessels and participates in inflammatory processes. Its excess production can increase the risk of cardiovascular diseases, so it is important to monitor the effects of thromboxane A2 and use drugs if necessary.[10]

Conclusion

Thromboxane A2 performs important biological functions in the human body and is of great importance in medicine. The role of thromboxane in the process of blood coagulation, in the management of the condition of blood vessels and in inflammatory processes is important in its clinical use. Medicines used as thromboxane inhibitors can be effective in preventing cardiovascular diseases and treating inflammatory diseases. Therefore, it is important to understand the importance of thromboxane in medicine and its clinical application in the health sector.

References:

1. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396–403
2. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827–30
3. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989;80:749–56
4. Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. Drugs 1988
5. Kenjayevich, B. A., Tashanovich, S. K., Uzokovich, D. M., & Sayfiyevna, У. S. (2022). Changes of basic intermediates in blood in myocardial infarction. *Journal of Positive School Psychology*, 1775-1781.
6. Советов, К. Т., & Байкулов, А. К. (2023). Динамика ИБС с корркекцией ЛДГ. *Modern Scientific Research International Scientific Journal*, *1*(9), 47-55.
7. Azim, B., Mustafo, D., Dusmurat, E., Saodat, У., Oksana, K., & Karokul, S. (2021). The state of free-radical oxidation of lipids in experimental myocardial infarction in rats. *European Journal of Molecular & Clinical Medicine*, *8*(3), 816-820.
8. Дониёрова, С. О., Байкулов, А. К., Саветов, К. Т., & Ташанов, О. С. (2023). ЭКСПЕРИМЕНТАЛЬНОЕ ОБОСНОВАНИЕ СОСТАВА ГРАНУЛ НА ОСНОВЕ СУХОГО ЭКСТРАКТА СОЛОДКИ. *PEDAGOGS*, *46*(1), 140-142.
9. Ташанов, О. С., & Саветов, К. Т. (2023). ЛЕКАРСТВЕННЫЕ РАСТЕНИЯ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ СЛИЗИСТОЙ ОБОЛОЧКИ РТА. *Research and Publications*, *1*(1), 42-45.

10. Kenjayevich, B. A., Tashanovich, S. K., & Hydoyatovna, I. F. (2022). Investigation of the skin-resorptive effect of manufactured chitosan. *european journal of modern medicine and practice*, *2*(5), 102-106.
11. Байкулов, А. К., Саветов, К. Т., & Халиков, К. М. (2020). РЕПАРАТИВНАЯ РЕГЕНЕРАЦИЯ КОЖИ ПРИ ЭКСПЕРИМЕНТАЛЬНОМ ТЕРМИЧЕСКОМ ОЖОГЕ С ИСПОЛЬЗОВАНИЕМ ХИТОЗАНА. In *АКТУАЛЬНЫЕ ПРОБЛЕМЫ БИОМЕДИЦИНЫ-2020* (pp. 291-292).
12. Sovetov, K. T., & Abdujabborova, S. Z. (2024). Change in Kinetic Parameters A-and B-Adrenoresceptors of Lymphocytes and Platelets in Patients with Acute Myocardial Infarction. *JOURNAL OF SCIENCE, RESEARCH AND TEACHING*, *3*(2), 4-6.
13. Tashanovich, S. Q., & Zulfiya, Q. (2024). Onkogenez biokimyosi. *SALOMATLIK VA HAYOT-FANI TADQIQOTLARI JURNALI*, *3*, 57-60.
14. Нурбаев, Х. И., Советов, К. Т., Рузиев, Э. А., & Ураков, Д. М. УДК547. 854. РЕАКЦИЯ АЛКИЛИРОВАНИЯ 2-Х ЗАМЕЩЕННЫХ ПИРИМИДИНОНОВ-4. *ILMIY AXBOROTNOMA*, 51.
15. Savetov, K. T., & Varfolomeev, S. D. (1997). Influence of ionizing radiation on α-and β-adrenoceptors of lymphocytes and thrombocytes. *Uzbekiston Biologiya Zhurnali*, *2*, 72-76.
16. Savetov, K. T., & Varfolomeev, S. D. (1997). Influence of ionizing radiation on {alpha}-and {beta}-adrenoceptors of lymphocytes and thrombocytes; Osobennosti vliyaniya ioniziruyushchego izlucheniya na {alpha}-i {beta}-adrenoretseptory limfotcitov i trombotsitov. *Uzbekskij Biologicheskij Zhurnal*, *2*.